Factor VIII F8 Antibodies

Affinity Biologicals, Inc. manufactures a broad range of Factor VIII F8 Antibodies which can be found in the listing below.   Further information about each individual Factor VIII antibody is available by following the associated links.  Our Factor VIII F8 Antibodies are excellent for use in immunoassays where high sensitivity is required and are frequently the preferred reagent for immunopreciptaion techniques and activity neutralization assays.  These antibodies have proven to be extremely useful in the preparation of immune-adsorbent resins for use in immuno-depletion of specific proteins from plasma as well as immuno-affinity purification of proteins.  Affinity’s Factor VIII F8 Antibodies are manufactured for use in research applications.

Factor VIII:C, HumanHostCatalogue No.Size
Purified IgGSheepSAF8C-IG10mg vial
Affinity Purified, IgGSheepSAF8C-AP0.5mg vial
Peroxidase Conjugated IgGSheepSAF8C-HRP0.2mg vial
Affinity Purified, FITC conjugated IgGSheepSAF8C-APFTC0.1mg vial
Affinity Purified, Biotinylated IgGSheepSAF8C-APBIO0.1mg vial
Matched Pair Antibodies for EIAF8C-EIA4 plates
Complete ELISA KitFVIII-AG1 plate

Factor VIII:C, CanineHostCatalogue No.Size
Purified IgGSheepSAC8C-IG0.5mg vial
Peroxidase Conjugated IgGSheepSAC8C-HRP0.2mg vial
Matched Pair Antibodies for EIACFVIII-EIA4 plates

Listing of Factor VIII F8 Antibodies

Description of Factor VIII (FVIII)

Factor VIII (formerly referred to as antihemophilic globulin and Factor VIII:C) is a large glycoprotein (320 kDa) that circulates in plasma at approximately 200 ng/ml. Synthesized in the liver, the majority of Factor VIII is cleaved during expression, resulting in a heterogeneous mixture of partially cleaved forms of FVIII ranging in size from 200-280 kDa. The FVIII is stabilized by association with von Willebrand Factor to form a FVIII-vWF complex required for the normal survival of FVIII in vivo (t1/2 of 8-12 hours).

F.VIII is a pro-cofactor that is activated through limited proteolysis by thrombin. In this process F.VIIIa dissociates from vWF to combine with activated Factor IX, calcium and a phospholipid surface where it is an essential cofactor in the assembly of the Factor X activator complex. Once dissociated from vWF, FVIIIa is susceptible to inactivation by activated Protein C and by non-enzymatic decay.

Hemophilia A is a congenital bleeding disorder resulting from an X-chromosome-linked deficiency of FVIII. The severity of the deficiency generally correlates with the severity of the disease. Some Hemophiliacs (~10%) produce a FVIII protein that is partially or totally inactive. The production of neutralizing antibodies to FVIII also occurs in 5-20% of Hemophiliacs 1-3.

References and Reviews

  1. Lollar P, Fay PJ, Fass DN; Factor VIII and Factor VIIIa. Methods in Enzymology, 222, pg 122, 1993.
  2. Hoyer, LW, Wyshock EG, Colman RW, in Hemostasis and Thrombosis, 3rd Edition, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp. 109-133, J.B. Lippincott Co., Philadelphia, 1994.
  3. Pittman DD, Kaufman RJ. Structure-Function Relationships of Factor VIII Elucidated through Recombinant DNA Technology. Thromb. Haemostas. 61:161-165, 1989.